Pacer Advisors Inc. Invests $1.50 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Pacer Advisors Inc. purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 1st quarter, Holdings Channel reports. The fund purchased 23,922 shares of the biotechnology company’s stock, valued at approximately $1,500,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tsfg LLC purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $25,000. Optiver Holding B.V. increased its position in shares of Arrowhead Pharmaceuticals by 83.8% during the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 186 shares during the period. iSAM Funds UK Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the third quarter valued at approximately $29,000. First Horizon Corp purchased a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $32,000. Finally, WPG Advisers LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 384.8% in the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 431 shares during the period. Institutional investors own 62.61% of the company’s stock.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the sale, the director owned 52,012 shares of the company’s stock, valued at $3,998,682.56. This trade represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals News Summary

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $120 price target, well above recent trading levels. The firm also raised its FY2030 EPS forecast to $5.42 from $4.64, suggesting analysts still expect substantial earnings growth from Arrowhead’s pipeline and commercialization prospects. Analysts Offer Insights on Healthcare Companies
• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to a loss of $3.45 from a loss of $3.75 and improved its Q4 2026 estimate to a loss of $1.35 from a loss of $1.51. These revisions point to somewhat better near-term results than previously expected.
• Neutral Sentiment: Arrowhead remains expected to report losses in FY2026 and FY2027, with consensus current-year EPS at a loss of $3.40. HC Wainwright’s forecast assumes profitability eventually emerges, including positive EPS in Q4 2027 and $5.42 EPS in FY2030.
• Negative Sentiment: HC Wainwright substantially reduced its EPS forecasts for FY2026, FY2027, FY2028 and FY2029, as well as Q1–Q4 2027. The FY2027 estimate was cut to a loss of $4.61 from $3.35, while the FY2028 estimate moved to a loss of $4.14 from $3.12. These revisions indicate greater expected spending or delayed revenue and could limit the stock’s gains.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $87.65 on Friday. The firm has a market cap of $12.35 billion, a price-to-earnings ratio of -38.96 and a beta of 1.27. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $15.01 and a 52-week high of $95.49. The company has a quick ratio of 6.23, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The company’s 50 day moving average is $79.97 and its 200 day moving average is $71.43.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million for the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The firm’s quarterly revenue was up 171.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.26) EPS. On average, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ARWR shares. JPMorgan Chase & Co. raised their price objective on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Morgan Stanley upped their target price on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Wall Street Zen raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. B. Riley Financial raised their price target on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Chardan Capital lifted their price objective on Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.